Fibromyalgia and psoriatic arthritis: Partners together

Littlejohn, Geoffrey

doi:10.1111/1756-185x.14029

Cited by 1 publication

(2 citation statements)

References 26 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Fibromyalgia (FM) is a chronic syndrome characterized by pain and tenderness, sleep disturbance, fatigue, cognitive dysfunction, and background emotional distress. It sometimes presents as a comorbidity with another disease or condition ( 144 ). FM is the clinical expression of stress-related neurobiological responses that lead to increased reactivity in several sensory neural systems, particularly those in the musculoskeletal system.…”

Section: Psoriatic Arthritis Comorbiditiesmentioning

confidence: 99%

“…In most patients with comorbid FM, such responses may be related to the burden of having a chronic illness. This includes the symptoms of the disease; the effect on general health; the need for tests, drugs, and treatments; disability; loss of quality of life; and changes in social and work roles ( 144 ). In the general population, the prevalence of FM varies, according to classification criteria, between 2 and 8%.…”

Section: Psoriatic Arthritis Comorbiditiesmentioning

confidence: 99%

See 1 more Smart Citation

Extra-Articular Manifestations and Comorbidities in Psoriatic Disease: A Journey Into the Immunologic Crosstalk

et al. 2021

View full text Add to dashboard Cite

Psoriatic arthritis (PsA) is a chronic inflammatory disease primarily affecting peripheral and axial joints, with the possible presence of extra-articular manifestations (EAMs), such as psoriasis, uveitis, and inflammatory bowel disease. Recently, the concept of psoriatic disease (PsD) has been proposed to define a systemic condition encompassing, in addition to joints and EAMs, some comorbidities (e.g., metabolic syndrome, type II diabetes, hypertension) that can affect the disease outcome and the achievement of remission. EAMs and comorbidities in PsA share common immunopathogenic pathways linked to the systemic inflammation of this disease; these involve a broad variety of immune cells and cytokines. Currently, various therapeutics are available targeting different cytokines and molecules implicated in the inflammatory response of this condition; however, despite an improvement in the management of PsA, comprehensive disease control is often not achievable. There is, therefore, a big gap to fill especially in terms of comorbidities and EAMs management. In this review, we summarize the clinical aspects of the main comorbidities and EAMs in PsA, and we focus on the immunopathologic features they share with the articular manifestations. Moreover, we discuss the effect of a diverse immunomodulation and the current unmet needs in PsD.

show abstract

Section: Psoriatic Arthritis Comorbiditiesmentioning

confidence: 99%

Section: Psoriatic Arthritis Comorbiditiesmentioning

confidence: 99%